Wassil Jim — SEC Form 4 filings
SEC reporting owner CIK 1813798. 33 Form 4 filings on record with FilingPulse; latest filed 2026-09-09.
Transaction summary — filings shown
Covers all 33 filings on record, filed 2024-02-05 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 68 legs across 23 filings — 113,837 shares, $9,671,949 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 67.
- Largest priced transaction: sale of 7,994 shares @ $116.14 ($928,399) in Vaxcyte, Inc., filed 2024-09-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | EVP, Chief Scientific Ofc, COO | 32 | — | 68 legs · 113,837 sh · $9,671,949 | 63 |
| Icosavax, Inc. (ICVX) | — | 1 | — | — | 4 |
Form 4 filings — Wassil Jim
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 1,381 @ $61.16 · Tax withholding (F): 5,459 @ $60.36 · Sale (S): 1,334 @ $59.52 | EDGAR |
| 2026-09-02 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 1,273 @ $60.74 · Option exercise (M): 2,250 @ $5.35 · Sale (S): 1,537 @ $60.89 · Sale (S): 713 @ $61.48 · Sale (S): 924 @ $60.95 · Sale (S): 303 @ $61.42 · +2 more | EDGAR |
| 2026-08-05 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 2,250 @ $5.35 · Sale (S): 861 @ $53.50 · Sale (S): 1,389 @ $54.09 · Option exercise (M): 2,250 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 516 @ $5.35 · Sale (S): 1,788 @ $56.03 · Sale (S): 456 @ $57.47 · Sale (S): 6 @ $57.82 · Option exercise (M): 516 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 1,949 @ $49.40 · Sale (S): 301 @ $50.26 | EDGAR |
| 2026-05-01 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 2,250 @ $56.83 | EDGAR |
| 2026-04-03 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 1,412 @ $58.14 · Sale (S): 838 @ $58.93 | EDGAR |
| 2026-03-11 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 975 @ $59.32 · Sale (S): 2,427 @ $58.32 · Sale (S): 4,968 @ $59.16 | EDGAR |
| 2026-03-02 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 32,045 @ $0 · Grant/award (A): 5,102 @ $61.74 · Tax withholding (F): 1,900 @ $61.74 · Tax withholding (F): 898 @ $61.98 · Tax withholding (F): 1,009 @ $61.98 · Grant/award (A): 53,566 (derivative) @ $0 | EDGAR |
| 2025-09-10 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 2,759 @ $32.41 | EDGAR |
| 2025-09-04 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 1,270 @ $31.56 · Tax withholding (F): 1,587 @ $31.56 · Tax withholding (F): 1,429 @ $31.56 | EDGAR |
| 2025-03-03 | 4 | Vaxcyte, Inc. (PCVX) | Gift (G): 74,000 @ $0 | EDGAR |
| 2025-03-03 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 21,726 @ $0 · Grant/award (A): 5,649 @ $73.02 · Tax withholding (F): 2,869 @ $73.02 · Tax withholding (F): 1,270 @ $73.02 · Option exercise (M): 2,638 @ $2.42 · Option exercise (M): 5,362 @ $5.35 · +6 more | EDGAR |
| 2025-02-04 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $2.42 · Sale (S): 5,314 @ $86.00 · Sale (S): 2,666 @ $86.67 · Sale (S): 20 @ $87.94 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $2.42 · Sale (S): 1,356 @ $82.88 · Sale (S): 5,483 @ $83.69 · Sale (S): 1,161 @ $84.43 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-12-03 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $2.42 · Sale (S): 5,772 @ $92.07 · Sale (S): 1,101 @ $93.06 · Sale (S): 1,127 @ $94.06 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 87,481 (derivative) @ $0 · Grant/award (A): 35,661 (derivative) @ $0 | EDGAR |
| 2024-11-04 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $2.42 · Sale (S): 4,955 @ $106.34 · Sale (S): 2,174 @ $107.20 · Sale (S): 631 @ $108.25 · Sale (S): 240 @ $108.93 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-10-29 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 1,585 @ $5.35 · Option exercise (M): 3,464 @ $20.93 · Option exercise (M): 1,585 (derivative) @ $0 · Option exercise (M): 3,464 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $2.42 · Sale (S): 2,312 @ $113.42 · Sale (S): 3,349 @ $114.31 · Sale (S): 2,339 @ $114.95 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-09-18 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 10,000 @ $2.42 · Sale (S): 1,784 @ $115.06 · Sale (S): 7,994 @ $116.14 · Sale (S): 222 @ $116.96 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 10,000 @ $2.42 · Sale (S): 258 @ $108.01 · Sale (S): 2,072 @ $110.08 · Sale (S): 3,102 @ $111.02 · Sale (S): 2,263 @ $111.85 · Sale (S): 367 @ $112.95 · +6 more | EDGAR |
| 2024-08-05 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 2,977 @ $78.84 · Sale (S): 23 @ $79.47 | EDGAR |
| 2024-07-02 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 1,226 @ $75.75 · Sale (S): 1,663 @ $76.71 · Sale (S): 111 @ $77.22 | EDGAR |
| 2024-06-05 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 1,634 @ $71.38 · Sale (S): 906 @ $72.32 · Sale (S): 460 @ $73.47 | EDGAR |
| 2024-05-03 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 1,753 @ $61.23 · Sale (S): 1,062 @ $61.99 · Sale (S): 185 @ $63.65 | EDGAR |
| 2024-04-19 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 3,551 @ $5.35 · Option exercise (M): 3,551 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 2,323 @ $66.53 · Sale (S): 677 @ $67.23 | EDGAR |
| 2024-03-19 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 4,099 @ $0 · Tax withholding (F): 1,484 @ $69.70 | EDGAR |
| 2024-03-04 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 20,000 @ $0 · Sale (S): 1,017 @ $73.08 · Sale (S): 1,220 @ $73.62 · Sale (S): 763 @ $74.69 · Tax withholding (F): 2,178 @ $71.55 · Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 27,917 @ $2.42 · Option exercise (M): 27,917 (derivative) @ $0 | EDGAR |
| 2024-02-20 | 4 | Icosavax, Inc. (ICVX) | Code (U): 3,695 · Disposition to issuer (D): 7,392 · Disposition to issuer (D): 44,556 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-02-05 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 3,000 @ $2.42 · Sale (S): 527 @ $72.18 · Sale (S): 1,056 @ $73.34 · Sale (S): 467 @ $74.14 · Sale (S): 950 @ $75.28 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1813798 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →